Overview
- 36 inspections across 34 sites are on record.
- 38 Form 483 observations are attributed to this investigator.
- Most recent recorded activity is 2019-11-19.
At a glance
Inspections
36
Sites
34
Observations
38
Career since
Jan 2008
Recent inspections
Most recent inspections in the published record.
| Site | Date | Category | Form 483 |
|---|---|---|---|
| Bristol-Myers Squibb Holdings Pharma Ltd. Liability Company | 19 Nov 2019 | Human Drugs | View 483 → |
| Novartis Pharma Stein AG | 25 Mar 2014 | Human Drugs | |
| ONESOURCE SPECIALTY PHARMA LIMITED | 22 Aug 2013 | Human Drugs | On file |
| ONESOURCE SPECIALTY PHARMA LIMITED | 12 Aug 2013 | Human Drugs | On file |
| Wockhardt Limited | 30 Jul 2013 | Human Drugs | On file |
Sites inspected
Bristol-Myers Squibb Holdings Pharma Ltd. Liability CompanyManati, United States1 insp.
Novartis Pharma Stein AGStein Ag, Switzerland1 insp.
ONESOURCE SPECIALTY PHARMA LIMITEDBengaluru, India1 insp.
ONESOURCE SPECIALTY PHARMA LIMITEDBengaluru, India1 insp.
Wockhardt LimitedKarodi, India1 insp.
Co-investigators
Investigators who share inspections with this person.
Barbara D Paul5 shared
Susan M Jackson3 shared
Carla A Norris2 shared
Mural B Gavini2 shared
Jose R Hernandez2 shared
Patsy J Domingo2 shared
Caroline H Le2 shared
Libia M Lugo1 shared
Kalavati C Suvarna1 shared
Xiaokuang Lai1 shared
Full investigator report
Get the verbatim findings behind Regina T Brown's 38 observations
Source 483 PDFs, verbatim observations, and how each site responded, so your team knows what they cite before they arrive.
- New inspections and Form 483s, mapped to the CFR citation
- Warning letter outcomes, and the citation patterns they repeat
- Their co-investigators, so no surprises about who shows up on site